<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078923</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353197</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2418</secondary_id>
    <nct_id>NCT00078923</nct_id>
  </id_info>
  <brief_title>Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate</brief_title>
  <official_title>Phase II Clinical Trial of Soy Isoflavones Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent or delay the&#xD;
      development of early cancer. Soy isoflavones may be effective in delaying the development of&#xD;
      early prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying different regimens of soy isoflavones to&#xD;
      compare how well they work in treating patients who are undergoing radical prostatectomy for&#xD;
      stage I or stage II prostate cancer (adenocarcinoma).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare blood/prostate biomarkers of oxidative stress and prostate cancer risk in&#xD;
           patients with stage I or II adenocarcinoma of the prostate treated with 3 different dose&#xD;
           levels of soy isoflavones before radical prostatectomy.&#xD;
&#xD;
        -  Compare prostatic tissue biomarkers of proliferation and apoptosis in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Determine the potential response, in terms of tumor and prostatic intraepithelial&#xD;
           neoplasia grade and volume, extraprostatic extension, and serum prostate-specific&#xD;
           antigen level, in patients treated with soy isoflavones and in those treated with&#xD;
           placebo.&#xD;
&#xD;
        -  Determine the safety of soy isoflavone supplementation in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel-group study.&#xD;
      Patients are stratified according to tumor stage (T1c vs T2). Patients are randomized to 1 of&#xD;
      4 treatment arms.&#xD;
&#xD;
        -  Arm I (control group): Patients receive oral placebo once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral soy isoflavones and oral placebo once daily.&#xD;
&#xD;
        -  Arm III: Patients receive a higher dose of oral soy isoflavones and oral placebo once&#xD;
           daily.&#xD;
&#xD;
        -  Arm IV: Patients receive a higher dose (higher than arm III) of oral soy isoflavones&#xD;
           once daily.&#xD;
&#xD;
      In all arms, treatment continues for 2-6 weeks (depending on the time from study entry to&#xD;
      planned surgery) in the absence of unacceptable toxicity. All patients then undergo radical&#xD;
      prostatectomy.&#xD;
&#xD;
      Patients are followed at 1 week.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (25 per treatment arm) will be accrued for this&#xD;
      study within 12.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative DNA damage as measured by 5-hydroxymethyluridine level</measure>
    <time_frame>at 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid oxidation as measured by 8-isoprostane level</measure>
    <time_frame>at 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor size, grade, and extension</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen and prostatic intraepithelial neoplasia grade</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of cell growth, differentiation, and apoptosis</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by number and grade of adverse events</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavones</intervention_name>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Prostatectomy or Brachytherapy</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Stage T1c or T2&#xD;
&#xD;
               -  Disease confined to the prostate gland&#xD;
&#xD;
          -  Planning to undergo radical prostatectomy within the next 3-4 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST less than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  Medically cleared for surgery&#xD;
&#xD;
          -  No concurrent thyroid disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biological therapy for prostate cancer&#xD;
&#xD;
          -  No concurrent biological agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for prostate cancer&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for prostate cancer&#xD;
&#xD;
          -  No concurrent thyroid hormone replacement medication&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 months since prior high-dose nutritional supplements&#xD;
&#xD;
          -  No concurrent regular use (more than once weekly) of soy products greater than 50 g of&#xD;
             soy protein or 50 mg of soy isoflavone&#xD;
&#xD;
          -  No concurrent high-dose nutritional supplements&#xD;
&#xD;
               -  Standard-dose single multivitamin tablet (e.g., Centrumâ„¢) allowed&#xD;
&#xD;
          -  No concurrent herbs&#xD;
&#xD;
          -  No concurrent soy foods&#xD;
&#xD;
          -  No other concurrent isoflavone supplements&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Kucuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

